Literature DB >> 19811547

Clinical guideline for male lower urinary tract symptoms.

Yukio Homma1, Isao Araki, Yasuhiko Igawa, Seiichiro Ozono, Momokazu Gotoh, Tomonori Yamanishi, Osamu Yokoyama, Masaki Yoshida.   

Abstract

This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate-specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as alpha(1)-blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non-urologists treat men with LUTS.

Entities:  

Mesh:

Year:  2009        PMID: 19811547     DOI: 10.1111/j.1442-2042.2009.02369.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  15 in total

Review 1.  A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms.

Authors:  Michael Erlano Chua; Jonathan Mendoza; Manuel See; Ednalyn Esmena; Dean Aguila; Jan Michael Silangcruz; Buenaventura Jose Reyes; Saturnino Luna; Marcelino Morales
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Development of a quality of life scale specific for patients with benign prostatic hyperplasia.

Authors:  Kamil Cam; Talha Muezzinoglu; Omer Aydemir; Recep Buyukalpelli; Gokhan Toktas; Hakan Gemalmaz
Journal:  Int Urol Nephrol       Date:  2013-02-19       Impact factor: 2.370

3.  The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  Naoya Masumori; Taiji Tsukamoto; Masahiro Yanase; Hiroki Horita; Masaharu Aoki
Journal:  Adv Urol       Date:  2010-10-26

4.  The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?

Authors:  Muhammet İhsan Karaman; Zülfü Sertkaya; Orhan Koca; Mehmet Akyüz; Mustafa Güneş; Metin İshak Öztürk
Journal:  Turk J Urol       Date:  2014-03

5.  Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.

Authors:  Naoya Masumori
Journal:  Ther Clin Risk Manag       Date:  2011-06-23       Impact factor: 2.423

6.  Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia.

Authors:  Tatsuo Morita; Kenji Komatsu Taro Kubo; Akira Fujisaki; Shinsuke Natsui; Akinori Nukui; Minoru Kobayashi; Shinsuke Kurokawa
Journal:  Res Rep Urol       Date:  2013-04-09

Review 7.  Korean clinical practice guideline for benign prostatic hyperplasia.

Authors:  Jeong Kyun Yeo; Hun Choi; Jae Hyun Bae; Jae Heon Kim; Seong Ok Yang; Chul Young Oh; Young Sam Cho; Kyoung Woo Kim; Hyung Ji Kim
Journal:  Investig Clin Urol       Date:  2016-01-11

8.  Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Authors:  Takashi Kawahara; Satoshi Morita; Hiroki Ito; Hideyuki Terao; Ryoko Sakata; Hitoshi Ishiguro; Katsuyuki Tanaka; Hiroshi Miyamoto; Junichi Matsuzaki; Yoshinobu Kubota; Hiroji Uemura
Journal:  BMC Urol       Date:  2013-06-12       Impact factor: 2.264

9.  The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis.

Authors:  Sung Won Lee; Jae Seung Paick; Hyun Jun Park; Ji Eon Won; Yoji Morisaki; Sebastian Sorsaburu; Lars Viktrup
Journal:  World J Mens Health       Date:  2014-04-25       Impact factor: 5.400

10.  Acupuncture for Chronic Urinary Retention due to Spinal Cord Injury: A Systematic Review.

Authors:  Jia Wang; Yanbing Zhai; Jiani Wu; Shitong Zhao; Jing Zhou; Zhishun Liu
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.